Search

A recent study conducted by researchers at the University of Turin in Italy has explored the use of subcutaneous immunoglobulin (SCIg) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). The study found that SCIg is as effective as intravenous immunoglobulin (IVIg) but offers several advantages, including better tolerance, easier administration, and improved quality of life for patients. The availability of highly concentrated subcutaneous solutions and new technological devices has further enhanced the delivery of SCIg. The study concludes that SCIg has become a well-established therapy for CIDP and provides a historical perspective on its evolution. [Extracted from the article]